Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults
Sponsor
U.S. Army Medical Research and Development Command (U.S. Fed)
Overall Status
Completed
CT.gov ID
NCT00350337
Collaborator
GlaxoSmithKline (Industry), Walter Reed Army Institute of Research (WRAIR) (U.S. Fed)
86
1
4
23.3
3.7
Study Details
Study Description
Brief Summary
This descriptive study will evaluate the safety and immunogenicity of 3 different formulations of the WRAIR dengue vaccine compared to a placebo.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Subjects will be randomized into one of 4 groups. One group will receive a placebo vaccine and the others will receive one of 3 different dengue vaccine formations. Each subject will receive two doses six months apart. Study subjects who elect to participate in a mosquito transmissibility component of the study will undergo mosquito feedings during each of the two assigned follow-up visits after vaccine dose 1. All subjects will have 11 venipunctures during 11 visits (i.e., screening plus 10 study visits) over a period of nine months.
A third (booster) dose of post transfection F17 or F19 will be administered approximately 5 to 12 months after dose 2 to all subjects who received one of these formulation for their first two doses. Volunteers will return for a single visit 6 months after receiving their booster dose (long term follow-up)
Study Design
Study Type:
Interventional
Actual Enrollment
:
86 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Phase II, Randomized, Observer-Blind, Single Center, Controlled Study of Two Doses of Various Formulations of WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to Placebo Control Administered on 0-6-Month Schedule to Healthy Adults
Actual Study Start Date
:
Apr 5, 2006
Actual Primary Completion Date
:
Jun 20, 2007
Actual Study Completion Date
:
Mar 13, 2008
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Pre-transfection F17 4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine |
Biological: Pre-transfection F17
Dengue tetravalent Vaccine F17 Pre transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
|
| Experimental: Post-transfection F17 4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lyophilized, single dose vials and sterile water for injection |
Biological: Post-transfection F17
Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
|
| Experimental: Post-transfection F19 4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lyophilized, single dose vials and sterile water for injection |
Biological: Post-transfection F19
Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
|
| Placebo Comparator: Placebo A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine. |
Other: Placebo
Sterile solution of buffered water (0.9% NaCl), U.S. FDA accepted vaccine excipient, phenol red dye(phenolsulfonphthalein, used in vaccines as a pH indicator); 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
|
Outcome Measures
Primary Outcome Measures
- N Antibody, Geometric Mean Titer(GMT) to Dengue Serotypes 1, 2, 3 and 4 [Pre dose 1, 1 month post dose 1, 7 months post dose 2, Pre dose 3 and 1 month post dose 3]
GMTs for DEN neut. antibodies -unprimed subjects (primary and booster ATP Cohort for immunogenicity) PRE = Pre dose PI(M1) = Post dose 1, month 1 PII(M7) = Post dose 2, month 7 PRE III = Pre dose 3 PIII(M1) = Post dose 3, month 1
- Percentage of Subjects Seropositive for Dengue Serotypes 1, 2, 3 and 4 [Pre dose 1, 1 month post dose 1, 7 months post dose 2, Pre dose 3 and 1 month post dose 3]
Serpositivity rates for DEN neut. antibodies -unprimed subjects (primary and booster ATP Cohort for immunogenicity) PRE = Pre dose PI(M1) = Post dose 1, month 1 PII(M7) = Post dose 2, month 7 PRE III = Pre dose 3 PIII(M1) = Post dose 3, month 1
- Occurrence of Any, and Grade 3 Solicited Adverse Events (AEs) Within 21 Days Follow-up After Dose 1 of Study Vaccine [21 days following 1st vaccination dose]
Diary cards, digital thermometers, and small rulers were provided to subjects to record local and general solicited symptoms(pain, redness and swelling at the injection site, fatigue, headache, pain behind the eyes, abdominal pain, nausea, vomiting, muscle aches, joint aches, rash, photophobia and pruritis) and oral temperature taken daily for 21 days (days 0 through 20). The observations were to be recorded each evening and account for the previous 24 hours. If multiple temperature measurements were taken throughout the day, the maximum temperature was to be recorded.
Secondary Outcome Measures
- Occurrence of Any, and Grade 3 Solicited Adverse Events (AEs) Within 21 Days Follow-up After Dose 2 of Study Vaccine; [within 21 days after vaccination]
- Unsolicited Adverse Events Within 31 Days After Each Dose of Study Vaccine Dose [within 31 days of study vaccine]
Summary of Unsolicited Adverse Events within 31 days after each dose of study vaccine dose (Primary total vaccinated cohort)
- Occurrence of Serious Adverse Events (SAEs) Throughout the Entire Study Period. [Days 0 to 270]
Serious adverse events will be recorded throughout the entire study period. Subjects instructed to contact the investigator immediately should they manifest any signs or symptoms they perceive as serious. An identification card and a set of phone numbers to contact study staff 24 hours a day, 7 days a week given to subjects.
- Occurrence of Abnormal Findings at Physical Examination After Each Vaccine Dose [throughout the 202 day study]
Abnormal findings at DEN physical examination were defined as: rash, generalized rash, hemorrhages (skin, conjunctival or mucosal), conjunctival injection, hepatomegaly, splenomegaly or lymphadenopathy; generalized lymphadenopathy (palpable lymph nodes in 4 or more of the following locations: cervical, axillary, inguinal or other with right and left sides considered as separate locations) positive tourniquet test (WHO criterion of 20 or more petechiae per 2.5 cm square)Results were reported positive/negative using the WHO criterion.
- Percentage of Subjects With Suspected and Confirmed Dengue Reported During the 31-day Post-vaccination Period (Total Vaccinated Cohort) [Days 0-30 post vaccination periods (total vaccinated cohort)]
The case definition of confirmed dengue used in this protocol requires fever (equivalent to an oral temperature ≥38.0ºC/≥ 100.4ºF) for three or more successive days, at least two of the signs or symptoms consistent with "suspected dengue" occurring during the period of fever, at least one clinical laboratory abnormality, and DEN viremia detected by RTqPCR. Cases not meeting all criteria were not considered "confirmed dengue." The percentage of subjects with suspected or confirmed dengue were tabulated by group after each vaccination.
- Neutralizing Antibody Sero-response to Each Dengue Serotype After Each Dose [Days 0 to 270]
Sero-response defined as: For initially seronegative(S-) subjects, antibody titer >=10 DE50 at PI(M1) For initially seropositive(S+) subjects, antibody titer at PI(M1) >=4 fold the pre-vacciniation neut. antibody titer
- Neutralizing Antibody Sero-response to Each Dengue Serotype After Each Dose (Continued) [Days 0 to 270]
Sero-response defined as: For initially seronegative(S-) subjects, antibody titer >=10 DE50 at PI(M1) For initially seropositive(S+) subjects, antibody titer at PI(M1) >=4 fold the pre-vacciniation neut. antibody titer
- Occurrence of Measurable Dengue Viremia at Specified Time Points Following Each Vaccine Dose. [Days 0 to 270]
For vireimia: Negative = GEQ/µl result is equal to zero Undetermined = GEQ/µL result is below LOD Positive = GEQ/µL result is >= LOD
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
-
A healthy male or female adult 18-45 years at the time of vaccination;
-
Free of obvious health problems as established by medical history and physical examination before entering into the study;
-
Written informed consent obtained from the subject;
-
Able to read the Subject Information Sheet and Consent Form;
-
Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study;
-
If the subject is female, she must be of non-childbearing potential, i.e. either surgically sterilized or one year post-menopausal; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions (i.e. intrauterine contraceptive device; oral contraceptives or other equivalent hormonal contraception, e.g. progestin implantable, cutaneous hormonal patch or injectable contraceptives) for 30 days prior to vaccination, have a negative pregnancy test within 48 hours prior to vaccination and must agree to continue such precautions for 60 days after completion of the vaccination series.
Exclusion Criteria:
-
Pregnant or lactating female;
-
Female planning to become pregnant or planning to discontinue abstinence or contraceptive precautions;
-
History of any neurological or behavioral disorder or seizures, with the exception of a single febrile seizure in childhood;
-
History of drug abuse or alcohol consumption (more than 2 drinks per day);
-
History of allergic disease/reaction likely to be exacerbated by any component of the vaccine;
-
History of urticaria related to mosquito bites requiring medical attention;
-
Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, renal, hematologic or endocrine functional defect, as determined by physical examination or laboratory tests;
-
Any confirmed or suspected immunosuppressive or immunodeficient condition;
-
Subject seropositive for HBsAg, anti-HCV or anti-HIV;
-
Acute disease at the time of enrollment (acute disease is defined as the presence of a moderate or severe illness with or without fever);
-
(Vaccine can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e., oral temperature <37.5°C/<99.5°F.)
-
Chronic hepatomegaly, right upper quadrant abdominal pain or tenderness;
-
Chronic splenomegaly, left upper quadrant abdominal pain or tenderness;
-
Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the study vaccine (includes placebo) or planned use during the study period;
-
Planned administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of the study vaccine and ending 30 days after;
-
A planned move to a location that will prohibit participating in the trial for 9 months after the initial vaccination;
-
Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 90 days preceding the first dose or planned administration during the study period. For corticosteroids, this will mean prednisone, or equivalent, 0.5 mg/kg/day. Inhaled and topical steroids are allowed;
-
Administration of immunoglobulins and/or blood products within 90 days preceding the first dose or planned administration during the study period;
-
Any chronic systemic drug therapy to be continued during the study period (except for vitamin/mineral supplements, a single anti-hypertension medication or routine treatment for gastro-esophageal reflux).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Walter Reed Army Institute of Research | Silver Spring | Maryland | United States | 20910 |
Sponsors and Collaborators
- U.S. Army Medical Research and Development Command
- GlaxoSmithKline
- Walter Reed Army Institute of Research (WRAIR)
Investigators
- Principal Investigator: Stephen J Thomas, MD, FACP, Walter Reed Army Institute of Research (WRAIR)
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
U.S. Army Medical Research and Development Command
ClinicalTrials.gov Identifier:
NCT00350337
Other Study ID Numbers:
- WRAIR 1151
- GSK 103996
- HSRRB A-13291
First Posted:
Jul 10, 2006
Last Update Posted:
Feb 12, 2021
Last Verified:
Feb 1, 2021
Additional relevant MeSH terms:
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 | Placebo |
|---|---|---|---|---|
| Arm/Group Description | 4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine. Pre-transfection F17: Dengue tetravalent Vaccine F17 Pre transfection: 1.0 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. | DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lot 1262. Lyophilized, single dose vials and sterile water for injection. Post-transfection F17: Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Tetravalent vaccine lot 1263. Lyophilized, single dose vials and sterile water for injection Post-transfection F19: Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine. Lot 1249. Lyophilized, single dose vials and sterile water for injection. Placebo: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. |
| Period Title: Overall Study | ||||
| STARTED | 22 | 22 | 21 | 21 |
| COMPLETED | 17 | 19 | 18 | 21 |
| NOT COMPLETED | 5 | 3 | 3 | 0 |
Baseline Characteristics
| Arm/Group Title | Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 | Placebo | Total |
|---|---|---|---|---|---|
| Arm/Group Description | 4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine. Pre-transfection F17: Dengue tetravalent Vaccine F17 Pre transfection: 1.0 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. | DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lot 1262. Lyophilized, single dose vials and sterile water for injection. Post-transfection F17: Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Tetravalent vaccine lot 1263. Lyophilized, single dose vials and sterile water for injection Post-transfection F19: Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine. Lot 1249. Lyophilized, single dose vials and sterile water for injection. Placebo: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. | Total of all reporting groups |
| Overall Participants | 22 | 22 | 21 | 21 | 86 |
| Age (Count of Participants) | |||||
| <=18 years |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Between 18 and 65 years |
22
100%
|
22
100%
|
21
100%
|
21
100%
|
86
100%
|
| >=65 years |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Age (years) [Mean (Standard Deviation) ] | |||||
| Mean (Standard Deviation) [years] |
35.9
(7.75)
|
32.8
(6.93)
|
33
(8.6)
|
35.8
(6.7)
|
34.3
(7.54)
|
| Sex: Female, Male (Count of Participants) | |||||
| Female |
6
27.3%
|
11
50%
|
8
38.1%
|
10
47.6%
|
35
40.7%
|
| Male |
16
72.7%
|
11
50%
|
13
61.9%
|
11
52.4%
|
51
59.3%
|
| Region of Enrollment (participants) [Number] | |||||
| United States |
22
100%
|
22
100%
|
21
100%
|
21
100%
|
86
100%
|
Outcome Measures
| Title | N Antibody, Geometric Mean Titer(GMT) to Dengue Serotypes 1, 2, 3 and 4 |
|---|---|
| Description | GMTs for DEN neut. antibodies -unprimed subjects (primary and booster ATP Cohort for immunogenicity) PRE = Pre dose PI(M1) = Post dose 1, month 1 PII(M7) = Post dose 2, month 7 PRE III = Pre dose 3 PIII(M1) = Post dose 3, month 1 |
| Time Frame | Pre dose 1, 1 month post dose 1, 7 months post dose 2, Pre dose 3 and 1 month post dose 3 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Number of subjects with titer within specified range |
| Arm/Group Title | Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 |
|---|---|---|---|
| Arm/Group Description | 4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine. Pre-transfection F17: Dengue tetravalent Vaccine F17 Pre transfection: 1.0 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. | DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lot 1262. Lyophilized, single dose vials and sterile water for injection; 0.5 mL F17Post vaccine Post-transfection F17: Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Tetravalent vaccine lot 1263. Lyophilized, single dose vials and sterile water for injection Post-transfection F19: Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. |
| Measure Participants | 16 | 16 | 15 |
| DEN-1: PRE |
2
|
2
|
2
|
| DEN-1: PI(M1) |
13
|
8
|
55
|
| DEN-1: PII(M7) |
195
|
46
|
98
|
| DEN-1: PRE III |
NA
|
10.2
|
30.3
|
| DEN-1: PIII(M1) |
NA
|
42.7
|
73.3
|
| DEN-2: PRE |
2
|
2
|
2
|
| DEN-2: P1(M1) |
141
|
49
|
168
|
| DEN-2: PII(M7) |
666
|
125
|
226
|
| DEN-2: PRE III |
NA
|
30
|
31.5
|
| DEN-2: PIII(M1) |
NA
|
100
|
194.5
|
| DEN-3: PRE |
2
|
2
|
2
|
| DEN-3: PI(M1) |
13
|
9
|
16
|
| DEN-3: PII(M7) |
78
|
27
|
48
|
| DEN-3: PRE III |
NA
|
4.1
|
10.1
|
| DEN-3: PIII(M1) |
NA
|
28.2
|
19.7
|
| DEN-4: PRE |
2
|
2
|
2
|
| DEN-4: PI(M1) |
16
|
30
|
28
|
| DEN-4: PII(M7) |
271
|
62
|
41
|
| DEN-4: PRE III |
NA
|
17.3
|
12.1
|
| DEN-4: PIII(M1) |
NA
|
44.4
|
32.2
|
| Title | Percentage of Subjects Seropositive for Dengue Serotypes 1, 2, 3 and 4 |
|---|---|
| Description | Serpositivity rates for DEN neut. antibodies -unprimed subjects (primary and booster ATP Cohort for immunogenicity) PRE = Pre dose PI(M1) = Post dose 1, month 1 PII(M7) = Post dose 2, month 7 PRE III = Pre dose 3 PIII(M1) = Post dose 3, month 1 |
| Time Frame | Pre dose 1, 1 month post dose 1, 7 months post dose 2, Pre dose 3 and 1 month post dose 3 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Vaccinated subjects for whom assay results were available. |
| Arm/Group Title | Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 |
|---|---|---|---|
| Arm/Group Description | 4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine. Pre-transfection F17: Dengue tetravalent Vaccine F17 Pre transfection: 1.0 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. | DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lot 1262. Lyophilized, single dose vials and sterile water for injection. Post-transfection F17: Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Tetravalent vaccine lot 1263. Lyophilized, single dose vials and sterile water for injection Post-transfection F19: Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. |
| Measure Participants | 16 | 16 | 15 |
| DEN-1: PRE |
0.0
0%
|
0.0
0%
|
0.0
0%
|
| DEN-1: PI(M1) |
43.8
199.1%
|
37.5
170.5%
|
66.7
317.6%
|
| DEN-1: PII(M7) |
92.9
422.3%
|
73.3
333.2%
|
83.3
396.7%
|
| DEN-1: PRE III |
NA
NaN
|
66.7
303.2%
|
71.4
340%
|
| DEN-1: PIII(M1) |
NA
NaN
|
83.3
378.6%
|
100
476.2%
|
| DEN-2: PRE |
0.0
0%
|
0.0
0%
|
0.0
0%
|
| DEN-2: PI(M1) |
87.5
397.7%
|
68.8
312.7%
|
86.7
412.9%
|
| DEN-2: PII(M7) |
100
454.5%
|
80.0
363.6%
|
100
476.2%
|
| DEN-2: PRE III |
NA
NaN
|
66.7
303.2%
|
57.1
271.9%
|
| DEN-2: PIII(M1) |
NA
NaN
|
83.3
378.6%
|
100
476.2%
|
| DEN-3: PRE |
0.0
0%
|
0.0
0%
|
0.0
0%
|
| DEN-3: PI(M1) |
50.0
227.3%
|
50.0
227.3%
|
60.0
285.7%
|
| DEN-3: PII(M7) |
71.4
324.5%
|
66.7
303.2%
|
83.3
396.7%
|
| DEN-3: PRE III |
NA
NaN
|
16.7
75.9%
|
42.9
204.3%
|
| DEN-3: PIII(M1) |
NA
NaN
|
83.3
378.6%
|
57.1
271.9%
|
| DEN-4: PRE |
0.0
0%
|
0.0
0%
|
0.0
0%
|
| DEN-4: PI(M1) |
37.5
170.5%
|
56.3
255.9%
|
53.3
253.8%
|
| DEN-4: PII(M7) |
78.6
357.3%
|
73.3
333.2%
|
66.7
317.6%
|
| DEN-4: PRE III |
NA
NaN
|
33.3
151.4%
|
42.9
204.3%
|
| DEN-4: PIII(M1) |
NA
NaN
|
83.3
378.6%
|
57.1
271.9%
|
| Title | Occurrence of Any, and Grade 3 Solicited Adverse Events (AEs) Within 21 Days Follow-up After Dose 1 of Study Vaccine |
|---|---|
| Description | Diary cards, digital thermometers, and small rulers were provided to subjects to record local and general solicited symptoms(pain, redness and swelling at the injection site, fatigue, headache, pain behind the eyes, abdominal pain, nausea, vomiting, muscle aches, joint aches, rash, photophobia and pruritis) and oral temperature taken daily for 21 days (days 0 through 20). The observations were to be recorded each evening and account for the previous 24 hours. If multiple temperature measurements were taken throughout the day, the maximum temperature was to be recorded. |
| Time Frame | 21 days following 1st vaccination dose |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 | Placebo |
|---|---|---|---|---|
| Arm/Group Description | 4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine. Pre-transfection F17: Dengue tetravalent Vaccine F17 Pre transfection: 1.0 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. | DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lot 1262. Lyophilized, single dose vials and sterile water for injection. Post-transfection F17: Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Tetravalent vaccine lot 1263. Lyophilized, single dose vials and sterile water for injection Post-transfection F19: Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine. Lot 1249. Lyophilized, single dose vials and sterile water for injection. Placebo: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. |
| Measure Participants | 22 | 22 | 21 | 21 |
| Any Grade 3 symptoms |
1
4.5%
|
1
4.5%
|
4
19%
|
3
14.3%
|
| General Grade 3 symptoms |
0
0%
|
0
0%
|
3
14.3%
|
2
9.5%
|
| Local Grade 3 symptoms |
1
4.5%
|
1
4.5%
|
1
4.8%
|
2
9.5%
|
| Title | Occurrence of Any, and Grade 3 Solicited Adverse Events (AEs) Within 21 Days Follow-up After Dose 2 of Study Vaccine; |
|---|---|
| Description | |
| Time Frame | within 21 days after vaccination |
Outcome Measure Data
| Analysis Population Description |
|---|
| Subjects with sufficient data to perform safety analysis |
| Arm/Group Title | Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 | Placebo |
|---|---|---|---|---|
| Arm/Group Description | 4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine. Pre-transfection F17: Dengue tetravalent Vaccine F17 Pre transfection: 1.0 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. | DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lot 1262. Lyophilized, single dose vials and sterile water for injection. Post-transfection F17: Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Tetravalent vaccine lot 1263. Lyophilized, single dose vials and sterile water for injection Post-transfection F19: Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine. Lot 1249. Lyophilized, single dose vials and sterile water for injection. Placebo: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. |
| Measure Participants | 16 | 19 | 18 | 20 |
| Any Grade 3 symptoms |
1
4.5%
|
1
4.5%
|
1
4.8%
|
0
0%
|
| General Grade 3 symptoms |
1
4.5%
|
1
4.5%
|
1
4.8%
|
0
0%
|
| Local Grade 3 symptoms |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Title | Unsolicited Adverse Events Within 31 Days After Each Dose of Study Vaccine Dose |
|---|---|
| Description | Summary of Unsolicited Adverse Events within 31 days after each dose of study vaccine dose (Primary total vaccinated cohort) |
| Time Frame | within 31 days of study vaccine |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 | Placebo |
|---|---|---|---|---|
| Arm/Group Description | 4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine. Pre-transfection F17: Dengue tetravalent Vaccine F17 Pre transfection: 1.0 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. | DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lot 1262. Lyophilized, single dose vials and sterile water for injection. Post-transfection F17: Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Tetravalent vaccine lot 1263. Lyophilized, single dose vials and sterile water for injection Post-transfection F19: Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine. Lot 1249. Lyophilized, single dose vials and sterile water for injection. Placebo: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. |
| Measure Participants | 22 | 22 | 21 | 21 |
| Any symptoms classified by MedDRA |
27
|
17
|
24
|
30
|
| Any symptoms reported |
27
|
17
|
24
|
31
|
| Grade 3 symptoms classified by MedDRA |
1
|
2
|
3
|
2
|
| Grade 3 symptoms reported |
1
|
2
|
3
|
2
|
| Casually related symptoms classified by MedDRA |
6
|
1
|
3
|
6
|
| Casually related symptoms reported |
6
|
1
|
3
|
7
|
| Grade 3 and casually related symptoms reported |
0
|
0
|
0
|
1
|
| Title | Occurrence of Serious Adverse Events (SAEs) Throughout the Entire Study Period. |
|---|---|
| Description | Serious adverse events will be recorded throughout the entire study period. Subjects instructed to contact the investigator immediately should they manifest any signs or symptoms they perceive as serious. An identification card and a set of phone numbers to contact study staff 24 hours a day, 7 days a week given to subjects. |
| Time Frame | Days 0 to 270 |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 | Placebo |
|---|---|---|---|---|
| Arm/Group Description | 4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine. Pre-transfection F17: Dengue tetravalent Vaccine F17 Pre transfection: 1.0 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. | DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lot 1262. Lyophilized, single dose vials and sterile water for injection. Post-transfection F17: Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Tetravalent vaccine lot 1263. Lyophilized, single dose vials and sterile water for injection Post-transfection F19: Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine. Lot 1249. Lyophilized, single dose vials and sterile water for injection. Placebo: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. |
| Measure Participants | 22 | 22 | 21 | 21 |
| Number [participants] |
0
0%
|
2
9.1%
|
1
4.8%
|
1
4.8%
|
| Title | Occurrence of Abnormal Findings at Physical Examination After Each Vaccine Dose |
|---|---|
| Description | Abnormal findings at DEN physical examination were defined as: rash, generalized rash, hemorrhages (skin, conjunctival or mucosal), conjunctival injection, hepatomegaly, splenomegaly or lymphadenopathy; generalized lymphadenopathy (palpable lymph nodes in 4 or more of the following locations: cervical, axillary, inguinal or other with right and left sides considered as separate locations) positive tourniquet test (WHO criterion of 20 or more petechiae per 2.5 cm square)Results were reported positive/negative using the WHO criterion. |
| Time Frame | throughout the 202 day study |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 | Placebo |
|---|---|---|---|---|
| Arm/Group Description | 4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine. Pre-transfection F17: Dengue tetravalent Vaccine F17 Pre transfection: 1.0 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. | DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lot 1262. Lyophilized, single dose vials and sterile water for injection. Post-transfection F17: Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Tetravalent vaccine lot 1263. Lyophilized, single dose vials and sterile water for injection Post-transfection F19: Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine. Lot 1249. Lyophilized, single dose vials and sterile water for injection. Placebo: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. |
| Measure Participants | 22 | 22 | 21 | 21 |
| Rash |
3
13.6%
|
1
4.5%
|
3
14.3%
|
0
0%
|
| Generalized Rash |
1
4.5%
|
0
0%
|
2
9.5%
|
0
0%
|
| Skin Hemorrhage |
0
0%
|
0
0%
|
0
0%
|
1
4.8%
|
| Conj. Hemorrhage |
0
0%
|
0
0%
|
0
0%
|
1
4.8%
|
| Conj. Injection 2 |
2
9.1%
|
1
4.5%
|
2
9.5%
|
1
4.8%
|
| Mucosal Hemorrhage |
2
9.1%
|
1
4.5%
|
1
4.8%
|
1
4.8%
|
| Lymphadenopathy |
4
18.2%
|
6
27.3%
|
7
33.3%
|
4
19%
|
| Generalized Lymphadenopathy |
0
0%
|
1
4.5%
|
0
0%
|
1
4.8%
|
| Hepatomegaly |
2
9.1%
|
3
13.6%
|
6
28.6%
|
4
19%
|
| Splemonegaly |
0
0%
|
1
4.5%
|
1
4.8%
|
2
9.5%
|
| Title | Percentage of Subjects With Suspected and Confirmed Dengue Reported During the 31-day Post-vaccination Period (Total Vaccinated Cohort) |
|---|---|
| Description | The case definition of confirmed dengue used in this protocol requires fever (equivalent to an oral temperature ≥38.0ºC/≥ 100.4ºF) for three or more successive days, at least two of the signs or symptoms consistent with "suspected dengue" occurring during the period of fever, at least one clinical laboratory abnormality, and DEN viremia detected by RTqPCR. Cases not meeting all criteria were not considered "confirmed dengue." The percentage of subjects with suspected or confirmed dengue were tabulated by group after each vaccination. |
| Time Frame | Days 0-30 post vaccination periods (total vaccinated cohort) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 | Placebo |
|---|---|---|---|---|
| Arm/Group Description | 4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine. Pre-transfection F17: Dengue tetravalent Vaccine F17 Pre transfection: 1.0 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. | DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lot 1262. Lyophilized, single dose vials and sterile water for injection. Post-transfection F17: Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Tetravalent vaccine lot 1263. Lyophilized, single dose vials and sterile water for injection Post-transfection F19: Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine. Lot 1249. Lyophilized, single dose vials and sterile water for injection. Placebo: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. |
| Measure Participants | 22 | 22 | 21 | 21 |
| Dose 1: Suspected Dengue |
4.5
20.5%
|
0
0%
|
0
0%
|
4.8
22.9%
|
| Dose 1: Confirmed Dengue |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Dose 2: Suspected Dengue |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Dose 2: Confirmed Dengue |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Title | Neutralizing Antibody Sero-response to Each Dengue Serotype After Each Dose |
|---|---|
| Description | Sero-response defined as: For initially seronegative(S-) subjects, antibody titer >=10 DE50 at PI(M1) For initially seropositive(S+) subjects, antibody titer at PI(M1) >=4 fold the pre-vacciniation neut. antibody titer |
| Time Frame | Days 0 to 270 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Vaccinated subjects for whom assay results were available. |
| Arm/Group Title | Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 | Placebo |
|---|---|---|---|---|
| Arm/Group Description | 4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine. Pre-transfection F17: Dengue tetravalent Vaccine F17 Pre transfection: 1.0 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. | DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lot 1262. Lyophilized, single dose vials and sterile water for injection. Post-transfection F17: Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Tetravalent vaccine lot 1263. Lyophilized, single dose vials and sterile water for injection Post-transfection F19: Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine. Lot 1249. Lyophilized, single dose vials and sterile water for injection. Placebo: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. |
| Measure Participants | 16 | 20 | 18 | 19 |
| S- (prior to vaccination) DEN-1 Month 1 |
43.8
|
35.3
|
66.7
|
0
|
| S+(prior to vaccination) DEN-1 Month 1 |
75
|
0
|
0
|
0
|
| S- (prior to vaccination) DEN-2 Month 1 |
87.5
|
70.6
|
86.7
|
0
|
| S+ (prior to vaccination) DEN-2 Month 1 |
50
|
33.3
|
33.3
|
0
|
| S- (prior to vaccination) DEN-3 Month 1 |
50.0
|
50.0
|
60.0
|
0
|
| S+ (prior to vaccination) DEN-3 Month 1 |
75
|
0
|
33.3
|
0
|
| S- (prior to vaccination) DEN-4 Month 1 |
37.5
|
52.9
|
53.3
|
11.1
|
| S- (prior to vaccination) DEN-5 Month 1 |
75.0
|
33.3
|
33.3
|
0
|
| Title | Neutralizing Antibody Sero-response to Each Dengue Serotype After Each Dose (Continued) |
|---|---|
| Description | Sero-response defined as: For initially seronegative(S-) subjects, antibody titer >=10 DE50 at PI(M1) For initially seropositive(S+) subjects, antibody titer at PI(M1) >=4 fold the pre-vacciniation neut. antibody titer |
| Time Frame | Days 0 to 270 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Vaccinated subjects for whom assay results were available. |
| Arm/Group Title | Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 | Placebo |
|---|---|---|---|---|
| Arm/Group Description | 4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine. Pre-transfection F17: Dengue tetravalent Vaccine F17 Pre transfection: 1.0 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. | DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lot 1262. Lyophilized, single dose vials and sterile water for injection. Post-transfection F17: Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Tetravalent vaccine lot 1263. Lyophilized, single dose vials and sterile water for injection Post-transfection F19: Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine. Lot 1249. Lyophilized, single dose vials and sterile water for injection. Placebo: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. |
| Measure Participants | 16 | 18 | 15 | 19 |
| S- (prior to vaccination) DEN-1 Month 7 |
92.9
|
73.3
|
83.3
|
5.6
|
| S+(prior to vaccination) DEN-1 Month 7 |
50.0
|
0
|
0
|
0
|
| S- (prior to vaccination) DEN-2 Month 7 |
100
|
80.0
|
100
|
0
|
| S+ (prior to vaccination) DEN-2 Month 7 |
0
|
33.3
|
33.3
|
0
|
| S- (prior to vaccination) DEN-3 Month 7 |
71.4
|
66.7
|
83.3
|
5.6
|
| S+ (prior to vaccination) DEN-3 Month 7 |
50.0
|
33.3
|
33.3
|
0
|
| S- (prior to vaccination) DEN-4 Month 7 |
78.6
|
73.3
|
66.7
|
0
|
| S- (prior to vaccination) DEN-5 Month 7 |
50.0
|
33.3
|
33.3
|
0
|
| Title | Occurrence of Measurable Dengue Viremia at Specified Time Points Following Each Vaccine Dose. |
|---|---|
| Description | For vireimia: Negative = GEQ/µl result is equal to zero Undetermined = GEQ/µL result is below LOD Positive = GEQ/µL result is >= LOD |
| Time Frame | Days 0 to 270 |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 | Placebo |
|---|---|---|---|---|
| Arm/Group Description | 4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine. Pre-transfection F17: Dengue tetravalent Vaccine F17 Pre transfection: 1.0 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. | DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lot 1262. Lyophilized, single dose vials and sterile water for injection. Post-transfection F17: Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Tetravalent vaccine lot 1263. Lyophilized, single dose vials and sterile water for injection Post-transfection F19: Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose. | A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine. Lot 1249. Lyophilized, single dose vials and sterile water for injection. Placebo: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. |
| Measure Participants | 22 | 22 | 21 | 21 |
| DEN-1 Dose 1 - Positive |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| DEN-1 Dose 1 - Undetermined |
2
9.1%
|
1
4.5%
|
2
9.5%
|
1
4.8%
|
| DEN-1 Dose 1 - Negative |
18
81.8%
|
21
95.5%
|
19
90.5%
|
20
95.2%
|
| DEN-1 Dose 1 - Missing |
2
9.1%
|
0
0%
|
0
0%
|
0
0%
|
| DEN-1 Dose 2 - Positive |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| DEN-1 Dose 2 - Undetermined |
1
4.5%
|
2
9.1%
|
2
9.5%
|
1
4.8%
|
| DEN-1 Dose 2 - Negative |
15
68.2%
|
17
77.3%
|
16
76.2%
|
19
90.5%
|
| DEN-1 Dose 2 - Missing |
6
27.3%
|
3
13.6%
|
3
14.3%
|
1
4.8%
|
| DEN-1 Overall Subject - Positive |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| DEN-1 Overall Subject - Undetermined |
3
13.6%
|
3
13.6%
|
3
14.3%
|
2
9.5%
|
| DEN-1 Overall Subject - Negative |
13
59.1%
|
16
72.7%
|
15
71.4%
|
18
85.7%
|
| DEN-1 Overall Subject - Missing |
6
27.3%
|
3
13.6%
|
3
14.3%
|
1
4.8%
|
| DEN- 2 Dose 1 - Positive |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| DEN- 2 Dose 1 - Undetermined |
1
4.5%
|
1
4.5%
|
0
0%
|
0
0%
|
| DEN- 2 Dose 1 - Negative |
18
81.8%
|
20
90.9%
|
19
90.5%
|
19
90.5%
|
| DEN- 2 Dose 1 - Missing |
3
13.6%
|
1
4.5%
|
2
9.5%
|
2
9.5%
|
| DEN- 2 Dose 2 - Positive |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| DEN- 2 Dose 2 - Undetermined |
0
0%
|
1
4.5%
|
1
4.8%
|
0
0%
|
| DEN- 2 Dose 2 - Negative |
15
68.2%
|
17
77.3%
|
15
71.4%
|
18
85.7%
|
| DEN- 2 Dose 2 - Missing |
7
31.8%
|
4
18.2%
|
5
23.8%
|
3
14.3%
|
| DEN- 2 Overall Subject - Positive |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| DEN- 2 Overall Subject - Undetermined |
0
0%
|
2
9.1%
|
1
4.8%
|
0
0%
|
| DEN- 2 Overall Subject - Negative |
15
68.2%
|
16
72.7%
|
15
71.4%
|
18
85.7%
|
| DEN- 2 Overall Subject - Missing |
7
31.8%
|
4
18.2%
|
5
23.8%
|
3
14.3%
|
| DEN- 3 Dose 1 - Postive |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| DEN- 3 Dose 1 - Undetermine |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| DEN- 3 Dose 1 - Negative |
20
90.9%
|
22
100%
|
21
100%
|
21
100%
|
| DEN- 3 Dose 1 - Missing |
2
9.1%
|
0
0%
|
0
0%
|
0
0%
|
| DEN- 3 Dose 2 - Postive |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| DEN- 3 Dose 2 - Undetermine |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| DEN- 3 Dose 2 - Negative |
16
72.7%
|
19
86.4%
|
18
85.7%
|
20
95.2%
|
| DEN- 3 Dose 2 - Missing |
6
27.3%
|
3
13.6%
|
3
14.3%
|
1
4.8%
|
| DEN- 3 Overall Subject - Positive |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| DEN- 3 Overall Subject - Undetermined |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| DEN- 3 Overall Subject - Negative |
16
72.7%
|
19
86.4%
|
18
85.7%
|
20
95.2%
|
| DEN- 3 Overall Subject - Missing |
6
27.3%
|
3
13.6%
|
3
14.3%
|
1
4.8%
|
| DEN- 4 Dose 1 - Positive |
2
9.1%
|
1
4.5%
|
0
0%
|
0
0%
|
| DEN- 4 Dose 1 - Undetermined |
1
4.5%
|
1
4.5%
|
1
4.8%
|
0
0%
|
| DEN- 4 Dose 1 - Negative |
17
77.3%
|
20
90.9%
|
20
95.2%
|
21
100%
|
| DEN- 4 Dose 1 - Missing |
2
9.1%
|
0
0%
|
0
0%
|
0
0%
|
| DEN- 4 Dose 2 - Postive |
3
13.6%
|
0
0%
|
0
0%
|
0
0%
|
| DEN- 4 Dose 2 - Undetermined |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| DEN- 4 Dose 2 - Negative |
13
59.1%
|
19
86.4%
|
18
85.7%
|
20
95.2%
|
| DEN- 4 Dose 2 - Missing |
6
27.3%
|
3
13.6%
|
3
14.3%
|
1
4.8%
|
| DEN- 4 Overall Subject - Positive |
5
22.7%
|
1
4.5%
|
0
0%
|
0
0%
|
| DEN- 4 Overall Subject - Undetermined |
1
4.5%
|
1
4.5%
|
1
4.8%
|
0
0%
|
| DEN- 4 Overall Subject - Negative |
11
50%
|
111
504.5%
|
17
81%
|
20
95.2%
|
| DEN- 4 Overall Subject - Missing |
5
22.7%
|
3
13.6%
|
3
14.3%
|
1
4.8%
|
Adverse Events
| Time Frame | Solicited local and general symptoms were assessed within the 21 day follow-up period (primary and booster total vaccinated cohort). Unsolicited symptoms were assessed within the 31 day post vaccination period (total vaccinated cohort). | |||||||
|---|---|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | ||||||||
| Arm/Group Title | Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 | Placebo | ||||
| Arm/Group Description | 4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine | monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lyophilized, single dose vials and sterile water for injection | 4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection. Lyophilized, single dose vials and sterile water for injection; 0.5 mL F19 vaccines | A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine. 0.5 mL for placebo | ||||
All Cause Mortality |
||||||||
| Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 | Placebo | |||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/22 (0%) | 0/22 (0%) | 0/21 (0%) | 0/21 (0%) | ||||
Serious Adverse Events |
||||||||
| Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 | Placebo | |||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/22 (0%) | 2/22 (9.1%) | 1/21 (4.8%) | 1/21 (4.8%) | ||||
| Injury, poisoning and procedural complications | ||||||||
| Procedural hypertension | 0/22 (0%) | 0 | 1/22 (4.5%) | 1 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||||||||
| Hodgkin's disease | 0/22 (0%) | 0 | 1/22 (4.5%) | 1 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Nervous system disorders | ||||||||
| axonal demyelinating polyneuropathy/bilateral upper and lower extremeties | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 0/21 (0%) | 0 |
| Social circumstances | ||||||||
| Rule out cerebral bleed secondary to assualt trauma (physical assault) | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
Other (Not Including Serious) Adverse Events |
||||||||
| Pre-transfection F17 | Post-transfection F17 | Post-transfection F19 | Placebo | |||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 19/22 (86.4%) | 19/22 (86.4%) | 16/21 (76.2%) | 13/21 (61.9%) | ||||
| Blood and lymphatic system disorders | ||||||||
| Anemia | 1/22 (4.5%) | 1 | 2/22 (9.1%) | 2 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
| Cardiac disorders | ||||||||
| Sinus tachycardia | 1/22 (4.5%) | 1 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Ear and labyrinth disorders | ||||||||
| Ear pain | 1/22 (4.5%) | 1 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Eye disorders | ||||||||
| Pain behind the eyes | 4/22 (18.2%) | 4 | 7/22 (31.8%) | 7 | 5/21 (23.8%) | 5 | 3/21 (14.3%) | 3 |
| Photophobia | 4/22 (18.2%) | 4 | 3/22 (13.6%) | 3 | 5/21 (23.8%) | 5 | 4/21 (19%) | 4 |
| Conjunctivitis | 0/22 (0%) | 0 | 1/22 (4.5%) | 1 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Gastrointestinal disorders | ||||||||
| Abdominal pain | 0/22 (0%) | 0 | 5/22 (22.7%) | 5 | 5/21 (23.8%) | 5 | 4/21 (19%) | 4 |
| Nausea | 6/22 (27.3%) | 6 | 5/22 (22.7%) | 5 | 4/21 (19%) | 4 | 2/21 (9.5%) | 2 |
| Vomiting | 2/22 (9.1%) | 2 | 3/22 (13.6%) | 3 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Diarrhea | 2/22 (9.1%) | 2 | 1/22 (4.5%) | 1 | 0/21 (0%) | 0 | 2/21 (9.5%) | 2 |
| Flatulence | 1/22 (4.5%) | 1 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 0/21 (0%) | 0 |
| Gastritis | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 0/21 (0%) | 0 |
| Gastroesophageal reflux disease | 0/22 (0%) | 0 | 1/22 (4.5%) | 1 | 1/21 (4.8%) | 1 | 0/21 (0%) | 0 |
| Gingival pain | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 0/21 (0%) | 0 |
| Tooth ache | 1/22 (4.5%) | 1 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 0/21 (0%) | 0 |
| General disorders | ||||||||
| Pain | 9/22 (40.9%) | 9 | 3/22 (13.6%) | 3 | 5/21 (23.8%) | 5 | 5/21 (23.8%) | 5 |
| Fatigue | 10/22 (45.5%) | 10 | 9/22 (40.9%) | 9 | 6/21 (28.6%) | 6 | 7/21 (33.3%) | 7 |
| Fever >37.5ºC | 5/22 (22.7%) | 5 | 7/22 (31.8%) | 7 | 3/21 (14.3%) | 3 | 5/21 (23.8%) | 5 |
| Axillary pain | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 0/21 (0%) | 0 |
| Chills | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
| Fatigue | 0/22 (0%) | 0 | 1/22 (4.5%) | 1 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Inflammation | 0/22 (0%) | 0 | 1/22 (4.5%) | 1 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Injection site bruising | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 0/21 (0%) | 0 |
| Swelling | 0/22 (0%) | 0 | 1/22 (4.5%) | 1 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Vessel puncture site hemorrage | 2/22 (9.1%) | 2 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Immune system disorders | ||||||||
| Hypersensitivity | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 0/21 (0%) | 0 |
| Infections and infestations | ||||||||
| Bronchitis | 1/22 (4.5%) | 14 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Fungal rash | 1/22 (4.5%) | 1 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Nasopharyngitis | 1/22 (4.5%) | 1 | 0/22 (0%) | 0 | 2/21 (9.5%) | 2 | 0/21 (0%) | 0 |
| Pharyngitis | 2/22 (9.1%) | 2 | 1/22 (4.5%) | 1 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
| Rhinitis | 1/22 (4.5%) | 1 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Tonsillitis | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 0/21 (0%) | 0 |
| Upper respiratory tract infection | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 0/21 (0%) | 0 |
| Injury, poisoning and procedural complications | ||||||||
| Redness | 8/22 (36.4%) | 8 | 3/22 (13.6%) | 3 | 5/21 (23.8%) | 5 | 5/21 (23.8%) | 5 |
| Swelling | 7/22 (31.8%) | 7 | 4/22 (18.2%) | 4 | 5/21 (23.8%) | 5 | 3/21 (14.3%) | 3 |
| Contusion | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
| Facial bones fracture | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
| Nerve injury | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 0/21 (0%) | 0 |
| Procedural pain | 1/22 (4.5%) | 1 | 2/22 (9.1%) | 2 | 3/21 (14.3%) | 3 | 1/21 (4.8%) | 1 |
| Thermal burn | 0/22 (0%) | 0 | 1/22 (4.5%) | 1 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Metabolism and nutrition disorders | ||||||||
| Gout | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 0/21 (0%) | 0 |
| Musculoskeletal and connective tissue disorders | ||||||||
| Arthralgia | 6/22 (27.3%) | 6 | 4/22 (18.2%) | 4 | 3/21 (14.3%) | 3 | 3/21 (14.3%) | 3 |
| Muscle aches | 6/22 (27.3%) | 6 | 5/22 (22.7%) | 5 | 4/21 (19%) | 4 | 4/21 (19%) | 4 |
| Back pain | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
| Muscle spasms | 1/22 (4.5%) | 1 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Musculoskeletal pain | 1/22 (4.5%) | 1 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 2/21 (9.5%) | 2 |
| Myalgia | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
| Pain in extremity | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
| Nervous system disorders | ||||||||
| Headache | 14/22 (63.6%) | 14 | 11/22 (50%) | 11 | 10/21 (47.6%) | 10 | 9/21 (42.9%) | 9 |
| Dizziness | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 2/21 (9.5%) | 2 |
| Headache | 1/22 (4.5%) | 1 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 1/21 (4.8%) | 1 |
| Tremor | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
| Psychiatric disorders | ||||||||
| Affect lability | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 1/21 (4.8%) | 1 |
| Insomnia | 2/22 (9.1%) | 2 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Reproductive system and breast disorders | ||||||||
| Dysmenorrhea | 0/22 (0%) | 0 | 1/22 (4.5%) | 1 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
| Ejaculation failure | 1/22 (4.5%) | 1 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Respiratory, thoracic and mediastinal disorders | ||||||||
| Cough | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 2/21 (9.5%) | 2 |
| Nasal congestion | 0/22 (0%) | 0 | 2/22 (9.1%) | 2 | 1/21 (4.8%) | 1 | 1/21 (4.8%) | 1 |
| Pharyngolaryngeal pain | 1/22 (4.5%) | 1 | 1/22 (4.5%) | 1 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Productive cough | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
| Sinus congestion | 1/22 (4.5%) | 1 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 1/21 (4.8%) | 1 |
| Wheezing | 0/22 (0%) | 0 | 1/22 (4.5%) | 1 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Skin and subcutaneous tissue disorders | ||||||||
| Pruritus | 9/22 (40.9%) | 9 | 3/22 (13.6%) | 3 | 3/21 (14.3%) | 3 | 4/21 (19%) | 4 |
| Rash | 7/22 (31.8%) | 7 | 3/22 (13.6%) | 3 | 3/21 (14.3%) | 3 | 0/21 (0%) | 0 |
| Dermatitis | 1/22 (4.5%) | 1 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Dermatitis contact | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 1/21 (4.8%) | 1 | 0/21 (0%) | 0 |
| Erythema | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
| Pruritus | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
| Skin irritation | 1/22 (4.5%) | 1 | 1/22 (4.5%) | 1 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
| Skin lesion | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
| Skin warm | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
| Social circumstances | ||||||||
| Physical assault | 0/22 (0%) | 0 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 1/21 (4.8%) | 1 |
| Surgical and medical procedures | ||||||||
| Phlebotomy | 1/22 (4.5%) | 1 | 0/22 (0%) | 0 | 0/21 (0%) | 0 | 0/21 (0%) | 0 |
Limitations/Caveats
[Not Specified]
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Division of Regulated Activities and Compliance Director |
|---|---|
| Organization | United States Army Medical Materiel Development Activity |
| Phone | 301-619-0317 |
| USAMRMCREGULATORYAFFAIRS@amedd.army.mil |
Responsible Party:
U.S. Army Medical Research and Development Command
ClinicalTrials.gov Identifier:
NCT00350337
Other Study ID Numbers:
- WRAIR 1151
- GSK 103996
- HSRRB A-13291
First Posted:
Jul 10, 2006
Last Update Posted:
Feb 12, 2021
Last Verified:
Feb 1, 2021